Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 161 | 0.820 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 8 | 0.660 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 5 | 0.660 |
Why?
|
| Enoxaparin | 1 | 2020 | 10 | 0.650 |
Why?
|
| Aortic Valve Stenosis | 1 | 2020 | 75 | 0.600 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 103 | 0.600 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2018 | 1 | 0.580 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2018 | 18 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 177 | 0.540 |
Why?
|
| Immunotherapy | 1 | 2019 | 152 | 0.540 |
Why?
|
| Anticoagulants | 1 | 2020 | 328 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 159 | 0.450 |
Why?
|
| Neoplasms | 2 | 2021 | 863 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 16 | 0.360 |
Why?
|
| Myeloproliferative Disorders | 1 | 2011 | 14 | 0.360 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2011 | 11 | 0.360 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2011 | 7 | 0.360 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 428 | 0.320 |
Why?
|
| Repressor Proteins | 1 | 2011 | 296 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 240 | 0.280 |
Why?
|
| Middle Aged | 10 | 2021 | 10090 | 0.270 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 124 | 0.240 |
Why?
|
| Survival Rate | 4 | 2020 | 452 | 0.240 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 808 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 47 | 0.220 |
Why?
|
| Mutation | 3 | 2021 | 2123 | 0.210 |
Why?
|
| Humans | 14 | 2021 | 40217 | 0.210 |
Why?
|
| Aged | 6 | 2020 | 8182 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 252 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 15 | 0.180 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 15 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 32 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 326 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 80 | 0.160 |
Why?
|
| Albumins | 1 | 2020 | 23 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2020 | 20 | 0.160 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 38 | 0.160 |
Why?
|
| Paclitaxel | 1 | 2020 | 56 | 0.160 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 257 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2021 | 168 | 0.160 |
Why?
|
| Vaccination | 1 | 2021 | 226 | 0.160 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 141 | 0.150 |
Why?
|
| Male | 8 | 2021 | 18271 | 0.150 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 20 | 0.150 |
Why?
|
| Geriatrics | 1 | 2019 | 29 | 0.150 |
Why?
|
| Female | 8 | 2021 | 20392 | 0.150 |
Why?
|
| Quality of Life | 2 | 2020 | 649 | 0.140 |
Why?
|
| Dihydropyrimidine Dehydrogenase Deficiency | 1 | 2017 | 1 | 0.130 |
Why?
|
| Capecitabine | 1 | 2017 | 7 | 0.130 |
Why?
|
| Fluorouracil | 1 | 2017 | 50 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2020 | 605 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 520 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 198 | 0.120 |
Why?
|
| Carboplatin | 1 | 2012 | 14 | 0.100 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 20 | 0.100 |
Why?
|
| Pyrazines | 1 | 2012 | 23 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 921 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 39 | 0.090 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 31 | 0.090 |
Why?
|
| Benzamides | 1 | 2011 | 35 | 0.090 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 7 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 114 | 0.090 |
Why?
|
| Triazoles | 1 | 2011 | 34 | 0.090 |
Why?
|
| Piperazines | 1 | 2011 | 55 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2011 | 79 | 0.090 |
Why?
|
| Nitriles | 1 | 2011 | 59 | 0.090 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 103 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 103 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 134 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2021 | 239 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 600 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1367 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2021 | 46 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 10255 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 151 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 134 | 0.040 |
Why?
|
| France | 1 | 2020 | 8 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2020 | 5 | 0.040 |
Why?
|
| Spain | 1 | 2020 | 16 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 11 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 9 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 37 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 89 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 91 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 2863 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 102 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 75 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 541 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 40 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 37 | 0.040 |
Why?
|
| beta Catenin | 1 | 2018 | 76 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 24 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2016 | 2 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 7 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 323 | 0.030 |
Why?
|
| United States | 2 | 2020 | 4886 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2016 | 71 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 78 | 0.030 |
Why?
|
| Bortezomib | 1 | 2012 | 18 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 21 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 34 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 270 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 142 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 3136 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1958 | 0.020 |
Why?
|